Daily non-political popular news in brief.

Cancer vaccines -- Taking a jab at cancer by stimulating the immune system

As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress. While HPV vaccine efforts had the "benefit" of a viral source for the disease, other researchers are developing vaccines for cancers that are not virally based, in an effort to coax the immune system into attacking cancerous cells.

Read more »

Keywords: cancer, vaccines, taking, jab, stimulating, immune, system, vaccine

« Previous | Next »

Similar news on "Cancer vaccines -- Taking a jab at cancer by stimulating the immune system":

1. Peptide vaccine fights off breast tumors with aid of bacteria-mimicking agents
   02-01-2007 · EurekAlert!
   With the help of immune system-stimulating molecules that mimic bacterial components, researchers have used a type of cancer vaccine to both delay and prevent breast tumors in mice. The strategy, they say, holds promise for the future use of peptide vaccines in women who are at high risk for developing breast cancer.
   Similar news · Read more »
   
2. Taking a Jab at Cancer
   08-11-2007 · Science News Online
   Vaccines that train a person's immune system to kill cancerous cells, when combined with drugs that block tumor defense mechanisms, are starting to show promise.
   Similar news · Read more »
   
3. Novel vaccine concept developed by scientists at the Wistar Institute
   01-31-2008 · EurekAlert!
   A new vaccine design strategy developed by scientists at the Wistar Institute could help to develop vaccines against diseases like AIDS and cervical cancer. The secret is using a herpes simplex protein called glycoprotein D to block a receptor molecule on antigen-presenting cells. Wistar scientists showed that vaccine vectors made by fusing glycoprotein D with genes from HIV and HPV antigens increase the immune system's response to those antigens in cell cultures and mice.
   Similar news · Read more »
   
4. Pancreatic cancer vaccine halts progression of disease in some patients
   04-17-2007 · EurekAlert!
   A dendritic cell-based therapeutic vaccine for pancreatic cancer developed by researchers at the University of Pittsburgh School of Medicine has successfully stalled the disease from progressing in a handful of patients three years post-vaccination. The results, part of a press briefing on cancer vaccines held at the annual meeting of the American Association of Cancer Research, provide promising evidence that the vaccine can trigger a patient's own immune system to rally against pancreatic cancer.
   Similar news · Read more »
   
5. Head and neck cancer vaccine targets proteins to create immune response
   04-17-2007 · EurekAlert!
   Researchers at the University of Pittsburgh Cancer Institute, in collaboration with the Gunma University School of Medicine in Japan, have developed a vaccine strategy for head and neck cancer that targets multiple peptides to activate the immune system to attack tumors. Their findings will be included in a press briefing on cancer vaccines at the annual meeting of the American Association for Cancer Research, April 14-18, at the Los Angeles Convention Center.
   Similar news · Read more »
   
6. From clinical cancer research: rethinking therapeutic cancer vaccine trials
   07-03-2007 · EurekAlert!
   Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient's immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way?
   Similar news · Read more »
   
7. Vaccine improves event-free survival for leukemia patients
   12-09-2007 · EurekAlert!
   Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than nonresponders, a team led by researchers at the University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.
   Similar news · Read more »
   
8. Biodegradable microspheres deliver time release vaccines, stimulate different immune response
   02-28-2007 · EurekAlert!
   A new vaccine delivery system using microspheres of a biodegradable polymer may not only reduce the need for booster shots in some cases, but also appears to stimulate an immune response that traditional vaccines do not. Researchers from Iowa State University report their findings today at the ASM Biodefense and Emerging Disease Research Meeting.
   Similar news · Read more »
   
9. Smallpox outbreak: How long would it take for vaccines to protect people? Would it work?
   04-30-2007 · EurekAlert!
   In the event of a smallpox outbreak in the United States, how long would it take for a vaccine to start protecting Americans by stimulating an immune response? A new national study led by Saint Louis University School of Medicine will attempt to answer this question.
   Similar news · Read more »
   
10. New target for HIV/AIDS drugs and vaccine discovered
    07-26-2007 · EurekAlert!
    Researchers from Rome, Italy, describe a finding in the August 2007 print issue of the FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection. In this report, researchers demonstrate for the first time how the HIV-1 Nef viral protein delivers a one-two punch to the body's innate immune system.
    Similar news · Read more »